Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Long-Term Survival after Invasive or Conservative Strategy in Elderly Patients with non-ST-Elevation Myocardial Infarction: A Prospective Cohort Study.

Kvakkestad KM, Gran JM, Eritsland J, Holst Hansen C, Fossum E, Andersen GØ, Halvorsen S.

Cardiology. 2019;144(3-4):79-89. doi: 10.1159/000503442. Epub 2019 Nov 5.

2.

Acoustic Features for the Identification of Coronary Artery Disease.

Schmidt SE, Holst-Hansen C, Hansen J, Toft E, Struijk JJ.

IEEE Trans Biomed Eng. 2015 Nov;62(11):2611-9. doi: 10.1109/TBME.2015.2432129. Epub 2015 May 12.

PMID:
25974927
3.

Partial oral treatment of endocarditis.

Iversen K, Høst N, Bruun NE, Elming H, Pump B, Christensen JJ, Gill S, Rosenvinge F, Wiggers H, Fuursted K, Holst-Hansen C, Korup E, Schønheyder HC, Hassager C, Høfsten D, Larsen JH, Moser C, Ihlemann N, Bundgaard H.

Am Heart J. 2013 Feb;165(2):116-22. doi: 10.1016/j.ahj.2012.11.006. Epub 2013 Jan 3.

PMID:
23351813
4.

Comparison of human adipose-derived stem cells and bone marrow-derived stem cells in a myocardial infarction model.

Rasmussen JG, Frøbert O, Holst-Hansen C, Kastrup J, Baandrup U, Zachar V, Fink T, Simonsen U.

Cell Transplant. 2014 Feb;23(2):195-206. doi: 10.3727/096368912X659871. Epub 2012 Dec 4.

PMID:
23211469
5.

[Necrotising fasciitis in a patient infected by Streptococcus pneumoniae].

Rostgaard-Knudsen M, Holst-Hansen C, Schønheyder HC.

Ugeskr Laeger. 2011 Jun 13;173(24):1732-4. Danish.

PMID:
21696680
6.

Segmentation of heart sound recordings by a duration-dependent hidden Markov model.

Schmidt SE, Holst-Hansen C, Graff C, Toft E, Struijk JJ.

Physiol Meas. 2010 Apr;31(4):513-29. doi: 10.1088/0967-3334/31/4/004. Epub 2010 Mar 5.

PMID:
20208091
7.

Gender differences in management and outcome of acute myocardial infarctions treated in 2006-2007.

Halvorsen S, Eritsland J, Abdelnoor M, Holst Hansen C, Risøe C, Midtbø K, Bjørnerheim R, Mangschau A.

Cardiology. 2009;114(2):83-8. doi: 10.1159/000216582. Epub 2009 May 7.

PMID:
19420934
8.

Can new pulmonary gas exchange parameters contribute to evaluation of pulmonary congestion in left-sided heart failure?

Moesgaard J, Kristensen JH, Malczynski J, Holst-Hansen C, Rees SE, Murley D, Andreassen S, Frokjaer JB, Toft E.

Can J Cardiol. 2009 Mar;25(3):149-55.

9.

Measurement of tumor load and distribution in a model of cancer-induced osteolysis: a necessary precaution when testing novel anti-resorptive therapies.

Amhlaoibh RN, Hoegh-Andersen P, Brünner N, Sørensen A, Winding B, Holst-Hansen C, Karsdal MA, Engsig MT, Delaissé JM, Heegaard AM.

Clin Exp Metastasis. 2004;21(1):65-74.

PMID:
15065604
10.

Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.

Winding B, NicAmhlaoibh R, Misander H, Høegh-Andersen P, Andersen TL, Holst-Hansen C, Heegaard AM, Foged NT, Brünner N, Delaissé JM.

Clin Cancer Res. 2002 Jun;8(6):1932-9.

11.

Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat.

Holst-Hansen C, Low JA, Stephens RW, Johnson MD, Carmeliet P, Frandsen TL, Brünner N, Dickson RB.

Breast Cancer Res Treat. 2001 Aug;68(3):225-37.

PMID:
11727959
12.

Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.

Ploug M, Østergaard S, Gårdsvoll H, Kovalski K, Holst-Hansen C, Holm A, Ossowski L, Danø K.

Biochemistry. 2001 Oct 9;40(40):12157-68.

PMID:
11580291
13.
15.

Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.

Holst-Hansen C, Hamers MJ, Johannessen BE, Brünner N, Stephens RW.

Br J Cancer. 1999 Sep;81(2):203-11.

16.

A new immunocapture assay for Escherichia coli beta-galactosidase for in vivo studies of lacZ-transduced tumor cells.

Holst-Hansen C, Brünner N, Johannessen BE, Felding J, Stephens RW.

Lab Invest. 1998 Dec;78(12):1643-4. No abstract available.

PMID:
9881965
17.

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM.

Nat Med. 1998 Aug;4(8):923-8.

18.

Effect of NCAM-transfection on growth and invasion of a human cancer cell line.

Edvardsen K, Bock E, Jirus S, Frandsen TL, Holst-Hansen C, Moser C, Spang-Thomsen M, Pedersen N, Walsh FS, Vindeløv LL, Brünner N.

APMIS. 1997 Dec;105(12):919-30.

PMID:
9463510
19.

MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.

Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA, Clarke R.

Cancer Res. 1997 Aug 15;57(16):3486-93.

20.

Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.

Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V, Brünner N.

Clin Exp Metastasis. 1996 May;14(3):297-307.

PMID:
8674284
21.

MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.

Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R.

Cancer Res. 1993 Jul 15;53(14):3229-32.

22.

[Breast cancer and polypeptide growth factors].

Rømer J, Holst-Hansen C, Moser C, Brünner N.

Nord Med. 1992;107(2):49-52. Danish.

PMID:
1538961

Supplemental Content

Loading ...
Support Center